Merck successfully divests Consumer Health

Closing of sale to Procter & Gamble at a cash purchase price of € 3.4 billion completed

03-Dec-2018 - Merck has successfully completed the sale of its Consumer Health business to Procter & Gamble (P&G), following close consultation with employee representatives, the approval of all relevant regulatory authorities and the fulfilment of other customary closing conditions. The successful completion ...

Merck to Sell Consumer Health to Procter & Gamble

Next step in Merck’s strategic focus on innovation driven businesses

19-Apr-2018 - Merck announced that it has signed an agreement to sell its global Consumer Health business to Procter & Gamble (P&G) for approximately €3.4billion in cash, or approximately $4.2billion at current exchange rates. The transaction, which is expected to close by the end of the fourth quarter ...

Scientists Crack the Gingivitis Genetic Code for First Time

Study Shows Nearly One-Third of Human Genome is Involved in Gingivitis

11-Dec-2009 - For the first time, US scientists have successfully identified gene expression and biological pathways involved in the onset and healing process of gingivitis, a condition affecting more than 50% of the UK adult population, and which if left untreated, can potentially lead to heart disease, ...

BioFocus DPI and Procter & Gamble sign compound management agreement

13-Aug-2009 - BioFocus DPI announced that it has signed a three year compound management agreement with Procter & Gamble Co. (P&G). Under the agreement, BioFocus DPI will manage P&G’s chemical library collection. These services will be provided by BioFocus DPI’s compound management facility in South San ...

Ablynx identifies novel Nanobodies achieving second milestone in Procter & Gamble collaboration

20-Jun-2007 - Ablynx has announced that its collaboration agreement with Procter & Gamble Pharmaceuticals Inc. (P&GP), a division of The Procter & Gamble Company, has reached a second milestone. Ablynx has discovered novel Nanobodies® against a second target for possible new treatments in the musculoskeletal ...

Ablynx and Procter & Gamble extend Nanobody drug discovery development agreement to metabolic targets

11-Apr-2006 - Ablynx has announced that its drug discovery and development alliance with Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company, has been extended to include metabolic disease targets. Through this agreement, Ablynx will use its unique and patent protected ...

Procter & Gamble Selects Evotec as Provider of Pharmaceutical Discovery and Chemical Development Services

25-Jul-2005 - Evotec AG and Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company announced that they have entered into agreements whereby Evotec will provide pharmaceutical discovery and chemical development services to P&GP. Under the terms of the agreements, P&GP will ...

7TM Pharma signs research agreement with Procter & Gamble

14-Apr-2005 - 7TM Pharma announced an agreement with Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company, under which the parties will undertake a joint research program within therapeutic angiogenesis with the aim of identifying development candidates for treatment of ...